Vericel Corp

VCEL

32.045USD

-1.485-4.43%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

13 / 177

Overall Ranking

94 / 4730

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

53.000

Target Price

+69.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 44.33% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 10.36M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is 204.27, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 57.26M shares, increasing 0.74% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.55M shares of this stock.

The company's current financial score is 7.43, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 52.60M, representing a year-over-year increase of 2.57%, while its net profit experienced a year-over-year increase of 191.20%.

Score

Industry at a Glance

Previous score

7.43

Change

0



Financials

9.08

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.52

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.20

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 234.15, which is 150.26% below the recent high of 585.97 and 138.87% above the recent low of -91.02.

Score

Industry at a Glance

Previous score

4.80

Change

-0.14

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/177

No Data

The company’s current earnings forecast score is 9.14, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Vericel Corp is 55.00, with a high of 62.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.25, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 38.41 and the support level at 33.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.41

Change

0.23

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 113.48%, representing a quarter-over-quarter increase of 3.22%. The largest institutional shareholder is The Vanguard, holding a total of 3.55M shares, representing 7.04% of shares outstanding, with 0.02% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.26M

-3.09%

The Vanguard Group, Inc.

Star Investors

3.48M

+0.20%

Brown Capital Management, LLC

2.88M

-10.93%

Conestoga Capital Advisors, LLC

2.06M

-0.38%

State Street Global Advisors (US)

2.44M

+1.35%

Fidelity Management & Research Company LLC

2.19M

+7.15%

Geneva Capital Management LLC

1.37M

+24.18%

Invesco Advisers, Inc.

1.98M

+3.17%

Congress Asset Management Company, LLP

1.48M

+1.55%

GW&K Investment Management, LLC

1.43M

+12.44%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.94, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Vericel Corp

VCEL

7.03 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BridgeBio Pharma Inc

BBIO

7.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Biogen Inc

BIIB

7.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.